A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Formulation and Determination of Intravenous Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs MEDI-7219 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors MedImmune
- 22 Jan 2018 Planned End Date changed from 16 Jul 2018 to 17 Aug 2018.
- 22 Jan 2018 Planned primary completion date changed from 16 Jul 2018 to 17 Aug 2018.
- 18 Dec 2017 Planned End Date changed from 20 Jul 2018 to 16 Jul 2018.